Ro 保险代理人考试试题cket Pharmace 保险代理人考试试题uticals Inc公司介绍
| 证券代码： |
RCKT |
上市板： |
主板 |
| 证券名称： |
Rocket Pharmaceuticals Inc |
上市场所： |
纳斯达克交易所 |
| 证券类型： |
普通股 |
发行方式： |
公开发售 |
| 首发上市日： |
2015/02/18 |
首发价格(元)： |
6 |
| 首发数量(股)： |
6,667,000 |
首发募资总额(US 保险代理人考试试题d/元)： |
40,002,000.00 |
Rocket Pharmaceuticals Inc基本资料
| 公司名称： |
Rocket Pharmaceuticals, Inc. |
注册地址： |
美国特拉华州 |
| 证券名称： |
Rocket Pharmaceuticals Inc |
上市场所： |
纳斯达克交易所 |
| 办公地址： |
保险代理人考试试题91 Hartwell Avenue, Lexington, Massachusetts, USA |
| 董事会主席： |
- |
成立日期： |
1999/07/07 |
| 公司属地： |
United States 美国 |
电话： |
+1 (781) 676-2100 |
| 公司网址： |
www.inotekpharma.com |
| 公司介绍： |
Rocket Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a first-in-class selective adenosine mimetic that the company rationally designed to lower IOP by restoring the eye’s natural pressure control mechanism. The company developed this molecule to selectively stimulate a particular adenosine subreceptor in the eye with the effect of augmenting the intrinsic function of the eye’s trabecular meshwork, or TM. The TM regulates the pressure inside the eye and is also the main outflow path for the fluid inside of the eye that often builds up pressure in patients with glaucoma. |